Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

2.50
Hdl Handle:
http://hdl.handle.net/11287/620598
Title:
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition
Authors:
Mikropoulos, C [et al]; McGrath, John S; Brewer, Carole
Abstract:
Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a known genetic predisposition to PrCa due to BRCA1/2 mutations. This analysis evaluates the utility of PSA and PSAV for identifying PrCa and high-grade disease in this cohort.
Citation:
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. 2018 Jan;118(2):266-276 Jan. British Journal of Cancer
Publisher:
Nature
Journal:
British Journal of Cancer
Issue Date:
4-Jan-2018
URI:
http://hdl.handle.net/11287/620598
DOI:
10.1038/bjc.2017.429
Additional Links:
https://www.nature.com/articles/bjc2017429
Note:
This article is freely available via Open Access. Click on the Additional Link above to access the full-text via the publisher's site.
Type:
Journal Article
Language:
en
Appears in Collections:
Urology; Clinical Genetics (Peninsula Genetics); 2018 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorMikropoulos, C [et al]en
dc.contributor.authorMcGrath, John Sen
dc.contributor.authorBrewer, Caroleen
dc.date.accessioned2018-01-11T10:05:49Z-
dc.date.available2018-01-11T10:05:49Z-
dc.date.issued2018-01-04-
dc.identifier.citationProstate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. 2018 Jan;118(2):266-276 Jan. British Journal of Canceren
dc.identifier.doi10.1038/bjc.2017.429-
dc.identifier.urihttp://hdl.handle.net/11287/620598-
dc.description.abstractProstate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a known genetic predisposition to PrCa due to BRCA1/2 mutations. This analysis evaluates the utility of PSA and PSAV for identifying PrCa and high-grade disease in this cohort.en
dc.language.isoenen
dc.publisherNatureen
dc.relation.urlhttps://www.nature.com/articles/bjc2017429en
dc.rightsArchived with thanks to British Journal of Cancer. This work is licensed under the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectWessex Classification Subject Headings::Urologyen
dc.titleProstate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predispositionen
dc.typeJournal Articleen
dc.identifier.journalBritish Journal of Canceren
dc.description.noteThis article is freely available via Open Access. Click on the Additional Link above to access the full-text via the publisher's site.en
dc.type.versionIn press (epub ahead of print)en
This item is licensed under a Creative Commons License
Creative Commons
All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.